Comparison
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 vs 11p15 4 Microduplication Syndrome C4749508
Clinical comparison between 17 Alpha Hydroxylase 7 20 Lyase Deficiency CN380063 and 11p15 4 Microduplication Syndrome for differential diagnosis and treatment planning.
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
A rare genetic disorder affecting steroid hormone production. Causes ambiguous genitalia, lack of puberty, and high blood pressure. Requires lifelong hormone replacement therapy.
11p15 4 Microduplication Syndrome C4749508
A rare genetic disorder involving duplication of material on chromosome 11, leading to varied developmental features. Requires individualized medical assessment.
6 comparison axes
Onset
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
0-18
11p15 4 Microduplication Syndrome C4749508
0-null
Onset patterns differ
Severity
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
severe
11p15 4 Microduplication Syndrome C4749508
moderate
Different severity levels
Chronic
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
Chronic
11p15 4 Microduplication Syndrome C4749508
Chronic
Differing course
Communicable
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
No
11p15 4 Microduplication Syndrome C4749508
No
Different transmission
Body System
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
endocrine
11p15 4 Microduplication Syndrome C4749508
congenital
Same/different system
Category
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
endocrine
11p15 4 Microduplication Syndrome C4749508
genetic
Different category
Bottom line
17-alpha-hydroxylase-7-20-lyase-deficiency-CN380063 and 11p15-4-microduplication-syndrome-C4749508 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 | 11p15 4 Microduplication Syndrome C4749508 | Discriminating power |
|---|---|---|---|
| Blood pressure | Hypertension is a reported feature and may begin in childhood or adolescence. | Hypertension is not established as a defining feature from the supplied description. | Moderate |
| Puberty and genital development | Ambiguous genitalia and absent or incomplete puberty are described. | These endocrine findings are not established; developmental features may vary. | High |
| Developmental profile | Primary developmental disability is not established by the supplied description. | Varied developmental features are reported and require individual assessment. | Moderate |
When to favor each condition
Choose 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 when
Hypertension with disordered puberty or ambiguous genitalia
This pattern fits an adrenal steroid-synthesis disorder better than a nonspecific chromosomal finding.
Moderate
Suspected congenital adrenal enzyme deficiency
The supplied description specifically implicates steroid hormone production.
High
Need for lifelong endocrine replacement is being considered
Hormone replacement is described for this condition, but the regimen must be specialist-directed.
Moderate
Choose 11p15 4 Microduplication Syndrome C4749508 when
Unexplained developmental differences without a clear endocrine pattern
The supplied description emphasizes varied developmental features and individualized assessment.
Moderate
Chromosomal microarray suggests extra 11p15.4 material
A confirmed duplication supports this diagnosis over an enzyme deficiency.
High
Family or clinician seeks syndrome-level genetic counseling
A chromosomal diagnosis has different inheritance and testing implications.
Moderate
How key tests differ
| Test | 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 | 11p15 4 Microduplication Syndrome C4749508 | Interpretation |
|---|---|---|---|
| Steroid hormone profile | Abnormal adrenal and sex-steroid pattern may be found; exact cutoffs are not stated here. | No characteristic steroid abnormality is established. | An abnormal result supports endocrine evaluation but is not itself a complete diagnosis. |
| Genetic testing | Testing may target the gene causing 17α-hydroxylase/17,20-lyase deficiency. | Chromosomal microarray or equivalent testing may show an 11p15.4 duplication. | The appropriate test depends on the suspected mechanism and clinician judgment. |
| Developmental assessment | Not the primary diagnostic test based on supplied data. | May document variable developmental strengths and needs. | Results guide support but do not alone distinguish the two conditions. |
Prognosis comparison
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
- Outcome
- A severe chronic endocrine condition is described; individual outcome is not quantified here.
- Factors
- Blood pressure control, hormone management, and timely specialist care may influence course.
11p15 4 Microduplication Syndrome C4749508
- Outcome
- A moderate but variable congenital condition is described; prognosis is not uniform.
- Factors
- The specific duplication, developmental profile, and associated findings may matter.
Time frame: Both may be lifelong; onset information is incomplete, especially for the right condition.
No comparative survival or complication rates are established.
Complications comparison
| Complication | Presentation |
|---|---|
| Hypertension-related effects | High blood pressure is described and may need long-term monitoring. Not established from the supplied source. Complications should be assessed individually; rates are not provided. |
| Pubertal or reproductive effects | Lack of puberty and genital ambiguity are described. Not established as characteristic. Endocrine and fertility implications require specialist interpretation. |
| Developmental or learning needs | Not established by the supplied description. Variable developmental features may create individualized support needs. Severity and functional impact are not uniform. |
Patient education highlights
- HighDifferent causes
One condition affects steroid production; the other involves duplicated chromosome 11 material. A shared rare-disease label does not mean the same care.
- HighSpecialist follow-up
Endocrine care may be central on the left, while genetics and developmental services may be central on the right.
- MediumAvoid unsupported numbers
Prevalence, exact laboratory cutoffs, mortality, and treatment doses are not established in this comparison.